comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 02:34:36 - browse：63

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： It's time to retire 'poor historian' from clinicians' vocabularies

focus

WSS

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Medtronic CEO on promising devices for diabetes, hypertension

FDA has safety concerns on CRISPR

Military medical care influenced by rank and race, new study finds

Military medical care influenced by rank and race, new study finds

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

focus

comprehensive

explore

The high cost of giving birth even with insurance

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Virginia high school admissions case could be legal follow

HIV vaccine remains elusive. Immunologists keep trying new ideas

The high cost of giving birth even with insurance

First Opinion Podcast: How to protect health care in times of war

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: New research from Sanofi, Regeneron, etc.

As demand for Covid shots wanes, Moderna seeks its next success

With measles on the rise, a personal story of a devastating disease

focus

HIV vaccine remains elusive. Immunologists keep trying new ideas

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Data integrity in scientific journals requires "effort" by publishers, institutions

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Diversifying clinical trials isn't enough to close racial gaps: study

Why Sanofi got shellacked over its spinoff

Wikipedia

focus

focus

focus